VitelyBio is a leading analytical contract research organization (CRO) offering a comprehensive range of in vitro, analytical, and microbiological solutions for various industries, including pharmaceutical, nutraceutical, herbal, and cosmetic. Founded in 2022, VitelyBio boasts state-of-the-art facilities, equipment, and instruments, with a team of experts in in vitro bioequivalence studies, in vitro characterization studies, pharmaceutical development, dissolution development, and microbiology.
The company prides itself on delivering accurate, timely, and reliable results throughout the product development and life cycle stages, following systematic R&D, rigorous regulatory standards, and quality & compliance. VitelyBio leverages scientific expertise, the latest technologies, and market and regulatory insights to help clients achieve their objectives and exceed expectations.
Capable of managing projects ranging from standard testing to complex studies, VitelyBio offers tailor-made protocols, methods, and processes to meet specific needs, requirements, and specifications. Whether in need of in vitro bioequivalence studies, in vitro characterization of pharmaceutical products, analytical services, or microbiological services, VitelyBio provides solutions for life science challenges.
There is no investment information
No recent news or press coverage available for VitelyBio.